Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Keyphrases

• Disease-modifying Therapy 100%
• Relapsing-remitting multiple Sclerosis 100%
• Phase II Trial 100%
• Alemtuzumab 100%
• Interferon beta-1a 54%
• Disability 18%
• Relapse Rate 18%
• Adverse Effects 9%
• Safety Assessment 9%
• Risk Management Strategies 9%
• Disease Activity 9%
• Rate Ratio 9%
• One Dose 9%
• Voice User Interface 9%
• Interferon-β (IFN-β) 9%
• Co-primary Endpoints 9%
• Early Identification 9%
• Treatment Refractory 9%
• Previously Untreated Patients 9%
• Glatiramer 9%
• Secondary Autoimmunity 9%
• Relapse Time 9%
• Anti-CD52 Monoclonal Antibody 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Multiple Sclerosis 100%
• Alemtuzumab 100%
• Diseases 100%
• Beta1a Interferon 50%
• Recurrence Risk 16%
• Safety Assessment 8%
• Adverse Event 8%
• Disease Activity 8%
• Beta Interferon 8%
• Glatiramer 8%